GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (OTCPK:NTBLQ) » Definitions » Asset Impairment Charge

NTBLQ (Notable Labs) Asset Impairment Charge : $0.00 Mil (TTM As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Asset Impairment Charge?

Notable Labs's Asset Impairment Charge for the three months ended in Jun. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 was $0.00 Mil.


Notable Labs Asset Impairment Charge Historical Data

The historical data trend for Notable Labs's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Asset Impairment Charge Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Asset Impairment Charge
- - -

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Asset Impairment Charge Get a 7-Day Free Trial - - - - -

Notable Labs Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.


Notable Labs Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Notable Labs's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.


Notable Labs Business Description

Traded in Other Exchanges
N/A
Address
320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.